Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SECRET-HF
NCT05774509Phase 1Active, not recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2023
- Primary completion
- Jul 2026
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of extracellular vesicle-enriched secretome of cardiovascular progenitor cells in dilated cardiomyopathy (DCM), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Serious Adverse Events at 12 months. Started May 2023; status: active, not recruiting.
02
Drugs
extracellular vesicle-enriched secretome of cardiovascular progenitor cells
03
Conditions
dilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on NCT05774509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05774509.